Vaxil Bio Ltd., a biotechnology company, focuses on a novel drug discovery and development platform based on signal peptides for infectious diseases and cancer. The company's lead product is ImMucin that has completed a Phase I/II clinical trial for the treatment of multiple myeloma. It is also developing a tuberculosis vaccine/treatment and a coronavirus (COVID-19) vaccine. The company has a collaboration agreement with The Tel Aviv Sourasky Medical Center for the company's research program to develop a potential peptide vaccine against COVID-19; and cooperative research and development agreement with U.S. Army Medical Research Institute of Infectious Diseases for testing CorVax for its ability to prevent COVID-19 in mice. The company was founded in 2006 and is headquartered in Toronto, Canada.

TSX:VXL

Vaxil Bio Ltd.

Last Close

0.01

23/07 20:00

Volume Today

4.43K

Avg: 77.78K

PE Ratio

−7.56

PFCF: −5.07

market

peer of

Earnings

Earnings per Share (Estimate*)

Revenue (Estimate*)

Metrics